MaxCyte, Inc. (NASDAQ:MXCT) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET

Company Participants

Sean Menarguez - Director of Investor Relations

Douglas Doerfler - Founder, President & Chief Executive Officer

Ronald Holtz - Interim Chief Financial Officer

Conference Call Participants

Julie Simmonds - Panmure Gordon

Madeline Mollman - William Blair

Daniel Arias - Stifel

Max Masucci - Cowen and Company

Hannah Hefley - Stephens Inc.

Vidyun Bais - BTIG

Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the MaxCyte Third Quarter Earnings Conference Call. [Operator Instructions]

At this time, I would like to turn the conference over to Mr. Sean Menarguez, Director of Investor Relations. Sir, please begin.

Sean Menarguez

Good afternoon, everyone. My name is Sean Menarguez, and I'm the Director of Investor Relations here at MaxCyte. Thank you all for participating in today's conference call. On the call for MaxCyte we have Doug Doerfler, President and Chief Executive Officer; and Ron Holtz, Interim Chief Financial Officer. Earlier today, MaxCyte released financial results for the third quarter ended September 30, 2022. A copy of the press release is available on the company's website.

Before we begin, I need to read the following statement. Statements or comments made during this call may be forward-looking statements within the meaning of federal securities laws. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. Actual results may differ materially from those expressed or implied in any forward-looking statements due to a variety of factors, which are discussed in detail in our SEC filings. The company undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise.

And with that, I'll turn the call over to Doug.

Douglas Doerfler

Well, thank you, Sean, and good afternoon, everyone, and thank you for joining MaxCyte's third quarter earnings call.

I will begin with a discussion of our business and operational highlights during the quarter, followed by a detailed financial review from Ron. We will then open the call for questions.

I am very pleased with our third quarter results as our team continues to deliver on the company's financial and strategic objectives. MaxCyte's platform continues to be the premier cell engineering technology for the industry, enabling the development of a growing set of advanced cell-based therapeutics. Throughout this year, we have invested in our people and capabilities as we seek to take advantage of the growing end markets and support our customers' and partners' growth.